The global opioids market size was valued at USD 27.13 billion in 2025 and is projected to grow from USD 27.66 billion in 2026 to USD 32.28 billion by 2034, registering a CAGR of 1.95% during the forecast period from 2026 to 2034. North America dominated the opioids market with a market share of 42.5% in 2025.
The opioid industry is poised for substantial growth due to increasing demand for pain, cough, and diarrhea treatments. Market players are primarily focusing on launching generic versions of various opioid drugs, driving accelerated market expansion throughout the forecast period.
Opioids are medications used to treat severe or persistent pain, such as chronic headaches and backaches, by patients recovering from surgery or experiencing severe pain associated with cancer, as well as by adults and children who have been injured while playing sports or who have been severely injured in falls, auto accidents, or other incidents. Narcotics is another term for opiates. Depending on the patient, the situation, and the type and level of pain, doctors prescribe different types of opioids with varying potencies that can be administered in various ways. Despite the fact that some opioids can be used to treat cough and diarrhea, the majority of opioid prescriptions are used to treat moderate to severe pain. Opioid prescription medications consist of hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and others. Opioids are the most frequently prescribed medications for the treatment of moderate to severe chronic pain. These analgesics are used to treat severe, constant pain in patients with terminal illnesses and to manage pain in cancer patients.
Download a Free Sample To learn more about this report,
Growing Preference for Safer and Ready-to-Administer Opioid Formulations
The opioids market is shifting toward carefully controlled products that improve dosing accuracy and reduce medication errors in hospitals. Manufacturers are introducing prefilled syringes, abuse-deterrent formulations, and lower-dose products for acute pain, surgery, anesthesia, and cancer care. Healthcare providers are also adopting multimodal pain management, where opioids are combined with non-opioid medicines to reduce the total opioid dose. Regulatory authorities are demanding clearer safety information about addiction, overdose, and long-term use. Consequently, companies must balance the continuing clinical need for strong analgesics with tighter prescribing practices, packaging safeguards, education programs, and post-market monitoring.
Persistent Need for Effective Treatment of Severe and Chronic Pain
Demand for opioids continues because these medicines remain important for managing severe pain that cannot be adequately controlled with other therapies. Cancer treatment, major surgery, traumatic injuries, palliative care, and advanced orthopedic conditions frequently require potent and rapidly acting analgesics. Population aging also increases the number of patients experiencing painful cancers, fractures, and degenerative diseases. Hospital demand is supported by injectable morphine and fentanyl used during anesthesia, intensive care, and postoperative recovery. In addition, methadone and buprenorphine serve important roles in treating opioid use disorder, expanding the market beyond conventional pain management while supporting closely supervised medical use.
Addiction Risks and Expanding Availability of Non-Opioid Alternatives
Addiction, respiratory depression, overdose, tolerance, and withdrawal remain major barriers to opioid prescribing and commercial growth. Governments and healthcare systems are encouraging shorter treatment periods, lower doses, prescription monitoring, and the use of alternative therapies whenever appropriate. Manufacturers face stronger warning requirements, liability exposure, controlled-production rules, and costly risk-management obligations. Competition is also increasing from non-opioid medicines that can treat acute pain without activating opioid receptors. These developments may reduce opioid use after common surgeries and injuries. Generic pricing pressure further limits revenue, while insurers may restrict coverage or require prior authorization for certain extended-release and high-potency products.
Expansion of Treatment Access and Development of Safer Therapies
Market opportunities are growing in opioid-use-disorder treatment, abuse-deterrent formulations, overdose reversal, and precisely dosed hospital products. Wider access to methadone and buprenorphine can increase demand through certified treatment programs, community clinics, correctional facilities, and telehealth-supported services. Companies can also develop formulations that resist crushing, dissolving, or injection while maintaining effective pain relief. Prefilled syringes and unit-dose packaging offer additional potential by reducing preparation time, contamination, and dosing mistakes in clinical settings. Research into longer-acting treatments and novel compounds may create products with improved adherence, fewer withdrawal symptoms, and lower misuse potential, particularly in underserved areas with limited addiction-care capacity.
Maintaining Medical Access While Preventing Misuse and Diversion
The central challenge is ensuring that patients with severe pain receive appropriate treatment without increasing misuse, diversion, or dependence. Restrictive policies can lower unnecessary prescribing, but overly tight controls may create shortages or delay care for cancer patients, surgical patients, and people receiving palliative treatment. Manufacturers must forecast legitimate demand under government production quotas while maintaining reliable supplies of controlled substances. Illicit fentanyl also complicates public understanding because deaths involving illegally manufactured products may be associated with the wider prescription-opioid category. Companies therefore require strong distribution controls, ongoing surveillance, clinician education, and clear communication to preserve trust and comply with changing regulations.
The pain management segment dominated the opioids market with a 76.4% market share, valued at USD 20.73 billion, and recorded a CAGR of 4.72%. Its leading position reflects the broad clinical use of opioids for managing moderate-to-severe pain across hospital, surgical, cancer-care, and other supervised treatment settings.
Request Customizationto receive a tailored report.
The fentanyl segment dominated the opioids market with an 18.7% market share, valued at USD 5.07 billion, and recorded a CAGR of 5.74%. Its leading position is supported by its high potency and suitability for tightly controlled dosing in anesthesia and other specialized medical procedures, giving it a distinct role within opioid-based treatment protocols.
Speak to an Analystto discuss market opportunities.
North America accounted for 42.5% of the global opioids market. The regional market was valued at USD 11.53 billion. North America is projected to grow at a CAGR of 4.35%.
U.S. retail opioid dispensing declined from 46.8 prescriptions per 100 people in 2019 to 35.4 in 2024. Tighter prescribing practices are shifting the market toward more controlled and clinically monitored pain management.
Canada has an established opioid agonist therapy system using medicines including buprenorphine and methadone for opioid use disorder. This creates a specialized treatment channel alongside conventional opioid analgesics.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 27.8% of the global opioids market. The regional market was valued at USD 7.54 billion. Europe is projected to grow at a CAGR of 4.12%.
Germany uses dedicated narcotic prescriptions for controlled medicines such as morphine, fentanyl and oxycodone, with specific documentation requirements. This regulatory structure keeps pharmaceutical opioid distribution closely tied to authorized prescribing and controlled dispensing.
UK clinical guidance recognizes opioids for acute and end-of-life pain while emphasizing their limited role in long-term chronic pain. This concentrates use around clearly defined clinical applications and stronger medication review.
Asia Pacific accounted for 19.4% of the global opioids market. The regional market was valued at USD 5.26 billion. Asia Pacific is projected to grow at a CAGR of 6.28%.
Japan maintains dedicated guidance for medical narcotics used in cancer pain treatment and their management. This connects opioid utilization closely with oncology and structured palliative-care pathways.
China's national medical insurance drug list includes commonly used opioid medicines such as fentanyl, morphine and oxycodone. Reimbursement coverage improves patient access to opioid analgesics within regulated clinical pain-management settings.
Latin America accounted for 6.1% of the global opioids market. The regional market was valued at USD 1.65 billion. Latin America is projected to grow at a CAGR of 4.76%.
Brazil places preparations containing opioids such as codeine and tramadol under controlled-prescription requirements, including prescription retention for specified formulations. Pharmacy-level dispensing controls therefore play a central role in legitimate product circulation.
The opioids market includes large generic-drug manufacturers, specialty pharmaceutical companies, and hospital-injectable suppliers. Teva, Pfizer, Hikma, Mallinckrodt, Endo, Sun Pharma, Amneal, and Fresenius Kabi compete through broad portfolios, manufacturing scale, regulatory approvals, and dependable hospital supply. Competition increasingly centers on prefilled syringes, differentiated delivery systems, generic availability, and products designed to reduce medication errors. Regulatory compliance and controlled-substance security are essential competitive factors, while opioid-related litigation has encouraged portfolio restructuring and stronger risk controls. Companies are also investing in non-opioid pain medicines and addiction treatments, creating a competitive environment that extends beyond conventional analgesic sales.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Medication Adherence Market Size, Share, Growth, 2034
Cytotoxic Drugs Market Size, Share, Growth, Analysis, Report, 2034
North America Aesthetic Medicine Market Size, Growth, Report to 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Asia Pacific Aesthetic Medicine Market Size, Top Share, Forecast to 2034
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com